Iterum Therapeutics (ITRM)
Iterum Therapeutics Statistics
Share Statistics
Iterum Therapeutics has 34.58M shares outstanding. The number of shares has increased by 108.89% in one year.
| Shares Outstanding | 34.58M |
| Shares Change (YoY) | 108.89% |
| Shares Change (QoQ) | 25.68% |
| Owned by Institutions (%) | 0.3% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,586 |
| FTD / Avg. Volume | 0.63% |
Short Selling Information
The latest short interest is 1.24M, so 3.59% of the outstanding shares have been sold short.
| Short Interest | 1.24M |
| Short % of Shares Out | 3.59% |
| Short % of Float | 3.67% |
| Short Ratio (days to cover) | 4.11 |
Valuation Ratios
The PE ratio is -1.41 and the forward PE ratio is -2.19. Iterum Therapeutics's PEG ratio is 0.02.
| PE Ratio | -1.41 |
| Forward PE | -2.19 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | -8.54 |
| P/FCF Ratio | -1.3 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Iterum Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of -11.16.
| Current Ratio | 1.41 |
| Quick Ratio | 1.41 |
| Debt / Equity | -11.16 |
| Debt / EBITDA | -2.44 |
| Debt / FCF | -1.7 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,752,666.67 |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 240K |
| Effective Tax Rate | -0.98% |
Stock Price Statistics
The stock price has increased by -31.65% in the last 52 weeks. The beta is 2.88, so Iterum Therapeutics's price volatility has been higher than the market average.
| Beta | 2.88 |
| 52-Week Price Change | -31.65% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 42.49 |
| Average Volume (20 Days) | 409,050 |
Income Statement
| Revenue | n/a |
| Gross Profit | -254K |
| Operating Income | -18.7M |
| Net Income | -24.77M |
| EBITDA | -18.7M |
| EBIT | -27.06M |
| Earnings Per Share (EPS) | -1.26 |
Balance Sheet
The company has 24.13M in cash and 45.53M in debt, giving a net cash position of -21.41M.
| Cash & Cash Equivalents | 24.13M |
| Total Debt | 45.53M |
| Net Cash | -21.41M |
| Retained Earnings | -486.07M |
| Total Assets | 44.59M |
| Working Capital | 7.18M |
Cash Flow
In the last 12 months, operating cash flow was -26.77M and capital expenditures -2K, giving a free cash flow of -26.77M.
| Operating Cash Flow | -26.77M |
| Capital Expenditures | -2K |
| Free Cash Flow | -26.77M |
| FCF Per Share | -1.36 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ITRM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ITRM is $5, which is 363% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 363% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 18, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 18, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -15.91 |
| Piotroski F-Score | 0 |